Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Mondelēz International Q4 2025 Earnings Call - Cocoa Drop Forces 2026 Flexibility; 2027 Margin Recovery Expected
Mondelēz ended 2025 having executed a chocolate price-pack playbook that protected margins in many markets, but a sudden, sharp fall in cocoa spot prices forced management to build flexibility into 20...
- A rapid decline in cocoa spot prices occurred in the last two weeks, creating short-term market uncertainty and potential competitive reactions that management cannot yet fully predict.
- Mondelēz is largely hedged for 2026 at higher pipeline cocoa costs, which produces a one-time inventory accounting adjustment and profit headwind concentrated in Q1 2026, quantified at about $500 million.
- Management views current cocoa prices as closer to historic norms, which should materially improve chocolate margins in 2027, with benefits split between reinvestment behind brands and EPS flow-through.
- +11 more takeaways
InnovAge Second Quarter Fiscal 2026 Earnings Call - Hit 9.2% Adjusted EBITDA Margin, Raised FY26 Guidance
InnovAge reported a clear operational turning point in Q2 fiscal 2026, posting revenue of $239.7 million, adjusted EBITDA of $22.2 million and net income of $11.8 million. Management says this quarter...
- Q2 revenue $239.7 million, adjusted EBITDA $22.2 million, net income $11.8 million for the quarter.
- Adjusted EBITDA margin 9.2% in Q2, the first time InnovAge hit its intermediate 8%–9% margin target.
- First half adjusted EBITDA $39.8 million, already above full-year fiscal 2025 adjusted EBITDA of $34.5 million.
- +15 more takeaways
Benchmark Q4 and Fiscal Year 2025 Earnings Call - Bookings Momentum and Early Signs of Semi-Cap Recovery
Benchmark closed 2025 with clear operational momentum: Q4 revenue of $704 million (up ~7% year over year) and non-GAAP EPS of $0.71, topping guidance. The company delivered 10.6% non-GAAP gross margin...
- Q4 revenue $704 million, up high single digits year over year (CFO cited 7%), with non-GAAP EPS $0.71, above guidance ($0.62-$0.68).
- Full-year 2025 revenue $2.66 billion, essentially flat vs prior year, with non-GAAP EPS $2.40, up 5% year over year. This marks five straight years of bottom-line growth outpacing the top line.
- Q4 non-GAAP gross margin 10.6%, up 50 basis points sequentially and 20 basis points year over year; Q4 operating margin reported at 5.5% and full-year non-GAAP operating margin 4.9%.
- +11 more takeaways
eGain Fiscal 2026 Q2 Earnings Call - AI Knowledge Hub Powers ARR Growth, Margin Expansion, and Cash Flow
eGain reported a clean quarter: revenue of $23.0 million, SaaS now 95% of sales, and profitability ahead of guidance. The company is seeing its AI Knowledge Hub accelerate customer adoption and econom...
- Total revenue $23.0 million in Q2, up 3% year over year, beating guidance and consensus.
- SaaS revenue increased 5% year over year and now accounts for 95% of total revenue, up from 93% a year ago.
- Excluding the sunsetting non-core messaging product (approx $600k per quarter), total revenue would have grown 5% and SaaS revenue would have grown 8% year over year.
- +12 more takeaways
Emerson Q1 2026 Earnings Call - Orders Surge 9% as Company Reiterates 2026 Targets and Lifts EPS Guide Despite Software Renewal Headwind
Emerson reported a solid Q1 with underlying orders up 9% and underlying sales up 2% year over year, driven by power, LNG, test and measurement, and software and systems. Management reiterated full-yea...
- Underlying orders rose 9% year over year in Q1, marking four consecutive quarters of strong order growth.
- Underlying sales increased 2% year over year in Q1, with price contributing about 3 points to growth.
- Adjusted segment EBITDA margin came in at 27.7%, above expectations, and adjusted EPS was $1.46, up 6% versus prior year.
- +14 more takeaways
8x8 Inc. Q3 2026 Earnings Call - Usage-based revenue surge and platform consolidation mark an inflection
8x8 reported a clear inflection quarter: third consecutive quarter of year‑over‑year service revenue growth, record service revenue, and the completion of the Fuze migration that consolidates the comp...
- Third consecutive quarter of year‑over‑year service revenue growth; Q3 service revenue $179.7M and total revenue $185M, both beating the high end of guidance by about $3M.
- Usage‑based offerings grew nearly 60% year‑over‑year and now represent ~21% of service revenue, up from ~14% a year ago.
- Voice AI interactions increased more than 200% and now account for the vast majority of AI interactions on the platform, with voice cited as the preferred channel for AI experiences.
- +12 more takeaways
Key Tronic Q2 FY2026 Earnings Call - $10.5M Restructuring Hit, China Wind‑Down as Vietnam and U.S. Ramps Try to Plug the Gap
Key Tronic reported a sharp top-line bite in Q2 FY2026, with revenue falling to $96.3 million from $113.9 million a year ago, driven largely by reduced demand from a longstanding customer and an end‑o...
- Q2 FY2026 revenue $96.3 million versus $113.9 million last year, decline driven by reduced demand from a longstanding customer and an End‑of‑Life program.
- First six months revenue $195.1 million versus $245.4 million in the prior year period.
- Company recorded approximately $10.5 million of restructuring charges this quarter, including severance and inventory write‑offs tied to the China wind‑down and Mexico workforce reductions.
- +12 more takeaways
Amgen Q4 2025 Earnings Call - Pipeline momentum centered on MariTide, Repatha and sustained portfolio breadth
Amgen closed 2025 with broad, operationally strong results and an aggressive 2026 playbook built around six growth pillars: Repatha, Evenity, Tezspire, rare disease, innovative oncology, and biosimila...
- Amgen reported double-digit revenue and EPS growth for 2025, driven by a broad portfolio where 14 products surpassed $1 billion in sales and 18 set company records.
- Management highlighted six momentum areas for 2026: Repatha, Evenity, Tezspire, rare disease, innovative oncology, and biosimilars, and expects these to offset headwinds from biosimilar competition and pricing pressure.
- MariTide is the company’s highest-profile late-stage program, now running six global phase 3 studies (two chronic weight management trials fully enrolled), ASCVD and heart failure outcome studies progressing, and two phase 3 sleep apnea studies beginning enrollment.
- +12 more takeaways
NGL Energy Partners Q3 FY2026 Earnings Call - Record Water Volumes, >$700M FY2027 Target and Nuclear MOU for Desalination
NGL reported a tidy operational quarter led by its Water Solutions business, setting new physical and paid-volume records and lifting adjusted EBITDA to $172.5 million. Management is leaning into wate...
- Adjusted EBITDA from continuing operations was $172.5 million in Q3 FY2026, up 9.2% year over year from $158.0 million.
- Water Solutions drove the quarter, with segment adjusted EBITDA of $154.5 million versus $132.7 million a year ago, a 16.5% increase.
- Physical produced water disposal hit ~3.07 million barrels per day in Q3, up 17.1% from the prior-year quarter, and total paid disposal was ~3.13 million bpd versus 2.91 million bpd, about a 7% rise.
- +16 more takeaways
Take-Two Interactive Q3 Fiscal 2026 Earnings Call - Raises FY Net Bookings After Mobile, NBA 2K and GTA Outperformance
Take-Two handily beat Q3 guidance, reporting net bookings of $1.76 billion and materially raising its full-year net bookings outlook to $6.65 to $6.7 billion, roughly $725 million above its May plan. ...
- Q3 net bookings of $1.76 billion, meaningfully above guidance of $1.55 to $1.6 billion.
- Take-Two raised full-year fiscal 2026 net bookings guidance to $6.65 to $6.7 billion, about 18% growth year-over-year at the midpoint and roughly $725 million above the May outlook.
- Recurrent consumer spending rose 23% in the quarter and comprised 76% of net bookings for the period.
- +15 more takeaways